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I and II are explored. Specific examples of botulinum neurotoxin genes are chosen for an in-depth discussion of neurotoxin gene evolution. The
most recent cases of foodborne botulism are summarised.
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Keywords: Clostridium botulinum; Botulism; Botulinum neurotoxin; Genomics; Neurotoxin gene cluster1. Introduction1.1. General properties of Clostridium botulinumC. botulinum is, unusually for a bacterial species, defined
by a single property that is the ability to produce botulinum
neurotoxin. Four discrete groups of bacteria are recognised
within C. botulinum. C. botulinum Groups I and II are pri-
marily responsible for human botulism, C. botulinum Group
III is responsible for botulism in various animal species, and
C. botulinum Group IV does not appear to be associated with
botulism in humans or animals [1e3]. C. botulinum Group I
(proteolytic C. botulinum) is a highly proteolytic bacterium
that can also degrade a range of carbohydrates (Table 1,
[4e6]). It is a mesophile, with minimum and optimum growth
temperatures of 12 C and 37 C, respectively (Table 1).
Spores formed by strains of C. botulinum Group I are highly
heat resistant, and the “Botulinum cook” (121 C/3 min) given
to low acid canned foods is designed to inactivate these spores.* Corresponding author.
http://dx.doi.org/10.1016/j.resmic.2014.10.010
0923-2508/© 2014 The Authors. Published by Elsevier Masson SAS on behalf of I
creativecommons.org/licenses/by/3.0/).The number of neurotoxin genes present in the genome, and
neurotoxins actually formed by strains of C. botulinum Group
I is variable, with strains possessing from one to three
neurotoxin genes, and forming one to three different neuro-
toxins [7,8]. Strains that possess two neurotoxin genes may
form either one active toxin (e.g. type A(B) strains form active
type A neurotoxin, but not active type B neurotoxin), or two
active toxins (e.g. type Ab strains form more type A neuro-
toxin than type B neurotoxin). Clostridium sporogenes is often
viewed as a non-toxigenic equivalent of C. botulinum Group I
(Table 1). C. botulinum Group II (non-proteolytic C. botuli-
num) is a highly saccharolytic bacterium that ferments a range
of carbohydrates (Table 1). It is a psychrotroph, with minimum
and optimum growth temperatures of 3.0 C and 30 C,
respectively (Table 1). Spores formed by strains of C. botuli-
num Group II are of moderate heat resistance (Table 1). Until
recently it was understood that all strains of C. botulinum
Group II possessed a single neurotoxin gene and formed a
single neurotoxin, however it was recently discovered that
strains of C. botulinum Group II type F also contain a fragment
of a type B and a type E neurotoxin gene [9]. Bacteria arenstitut Pasteur. This is an open access article under the CC BY license (http://
Table 1
Characteristics of Clostridium botulinum Groups I and II [4e6].
Neurotoxigenic clostridia C. botulinum
Group I (proteolytic
C. botulinum)
C. botulinum Group II
(non-proteolytic
C. botulinum)
Neurotoxins formed A, B, F, Ha B, E, F
Ferment glucose þb þ
Ferment maltose v þ
Ferment fructose v þ
Ferment sucrose  þ
Ferment mannose  þ
Proteolysisc þ 
Liquefaction of gelatinc þ þ
Lipase production þ þ
Lecithinase  
Degradation of chitin þ þ
Minimum growth
temperature
12 C 3 C
Optimum growth
temperature
37 C 30 C
Minimum pH for growth 4.6 5.0
NaCl concentration
preventing growth
10% 5%
Minimum water activity
for growth with NaCl
0.94 0.97
Minimum water activity
for growth with glycerol
0.93 0.94
Spore heat resistanced D121C ¼ 0.21 min D82.2C ¼ 2.4/231 mine
Non-neurotoxigenic
equivalent clostridia
C. sporogenes No species name given
a More than one toxin type may be formed; type H neurotoxin not yet
verified, see text.
b þ all strains positive, v some strains are positive and others negative,  all
strains negative.
c Proteolysis denotes an ability to degrade native proteins (e.g. coagulated
egg white, cooked meat particles, casein). Both C. botulinum Groups I and II
can degrade the derived protein, gelatine.
d Decimal reduction time (D-value; i.e. time to a ten-fold reduction in viable
spores) at specified temperature determined in phosphate buffer, pH 7.0.
e D-value without/with lysozyme during recovery.
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form neurotoxin; however they have not yet been given a
formal name.1.2. General properties of the botulinum neurotoxinsFig. 1. Two major neurotoxin cluster arrangements in C. botulinum Group I
and C. botulinum Group II [11]. Note that the botR gene, the product of which
acts as a positive regulator for expression of the neurotoxin gene cluster, is not
present in C. botulinum Group II orf-X neurotoxin gene clusters.There are seven confirmed major botulinum neurotoxins
(types AeG, with type H recently reported but yet to be
verified [10,11]) and more than thirty different subtypes [12].
Botulinum neurotoxins are the most potent naturally-occurring
substance, with as little as 30e100 ng (3000 MLD50 (mouse
minimum lethal doses)) of neurotoxin sufficient to cause
human botulism. This estimate is based on the amount of
neurotoxin consumed in cases of foodborne botulism and from
various animal experiments [13e15]. Botulinum neurotoxins
are 150 kDa proteins that comprise a heavy chain (100 kDa)
and a light chain (50 kDa). The heavy chains have two
functional domains. The C-terminal domain is involved in
neurotoxin binding to the nerve cell, with the N-terminal
domain involved in movement of the light chain into the
cytoplasm of the nerve cell. The light chains are zincendopeptidases that are active within the nerve cell. Here they
selectively cleave proteins (e.g. SNAP-25, VAMP) of the
neurotransmitter-vesicle docking/fusion complex, destabilis-
ing this complex. This prevents neurotransmitter release and
leads to a flaccid muscle paralysis [16,17]. C. botulinum
Group I (proteolytic) strains form neurotoxins only of type A,
B, F and H; strains of C. botulinum Group II (non-proteolytic)
form neurotoxins of type B, E or F (Table 1).
The botulinum neurotoxins form complexes with accessory
proteins (e.g. haemagglutinin (HA) and non-toxic-non-
haemagglutinin (NTNH)) of various sizes from 300 kDa to
900 kDa. These accessory proteins protect the neurotoxin and
may facilitate its absorption into the body. Indeed a recent
publication has shown that the haemagglutinin complex of the
type A neurotoxin specifically binds the cell adhesion protein,
E-cadherin, compromising the tight junction between gut
epithelial cells to facilitate absorption of the neurotoxin
complex from the gut lumen into the body [18]. Genes
encoding the neurotoxins and accessory proteins are situated
together in one of two conserved neurotoxin clusters (ha
cluster and orf-X cluster), both of which comprise two tran-
scriptional units (Fig. 1). For C. botulinum Groups I and II,
these are located on the chromosome or a plasmid [5]. One
transcriptional unit in the ha cluster encodes genes for the
neurotoxin and NTNH, while a second transcriptional unit
(transcribed in the opposite direction) encodes three HA genes
(Fig. 1). A gene encoding a positive regulator (sigma 70
factor) of the ha cluster is located between these two tran-
scriptional units [19]. The orf-X cluster includes a transcrip-
tional unit encoding genes for the neurotoxin and NTNH (as
with the ha cluster). The second transcriptional unit contains a
group of three open reading frames of unknown function (orf-
X1, orf-X2, orf-X3) and lacks the three HA encoding genes.
The orf-X cluster contains a gene ( p47) of unknown function;
interestingly, the gene encoding the positive regulatory protein
(botR) also appears to be present in the orf-X neurotoxin gene
cluster in strains of C. botulinum Group I, but not in those of
C. botulinum Group II (Fig. 1). Other differences between
otherwise closely related neurotoxin gene clusters have been
noted, which are presumably indicators of past DNA
Table 2
Examples of recent incidents of foodborne botulism.
Outbreak Probable cause of outbreak Number of
cases (deaths)
C. botulinum
Group
Toxin type Reference
Home-made fermented beaver tail and
paw
(USA, 2001)
Temperature abuse 3 (0) II E [23]
Home-made, fermented salmon roe (2
outbreaks)
(Canada, 2001)
Temperature abuse 4 (0) II E [24]
Raw “muktuk” (skin and blubber from
beluga whale, stored in sealed plastic
bags)
(USA, 2002)
Temperature abuse enabling growth
and toxin production in sealed bag
12 (0) II E [25]
Home-salted, air-dried fish
(Germany, 2003)
Fish gutted, salted in brine, dried, no
refrigeration
3 (0) II E [26]
Home-made “rakfisk”
(Norway, 2003)
Inadequate salt and inadequate
refrigeration
4 (0) II E [26]
Green olives preserved using salt
(Italy, 2004)
No lethal heat treatment, no controlled
inhibitory conditions
28 (0) I? B [27]
Illicit prison alcohol “pruno”, made
with potatoes (2 unlinked outbreaks)
(USA, 2004)
Mild heat treatment, maintenance at
ambient temperature
5 (0) I A [28]
Home-made suzme (condensed
yoghurt)
(Turkey, 2005)
Condensed yoghurt filled into plastic
jars and buried in earth for 2 months.
Yoghurt in one jar had been in contact
with soil.
10 (2) I A [29]
Home-dried fish
(Kazakhstan, 2005)
Inadequate processing (?) 25 (1) II? E? [30]
Home-prepared, uneviscerated, salted
fish
(USA, 2005)
Uneviscerated fish with salt placed in
sealed plastic bag and stored at ambient
temperature for ~ I month
5 (0) II E [31]
Traditional soup (“Ashmast”)
(Iran, 2006)
Soup included spinach that had been
stored in an airtight container
11 (0) II E [32]
Home-canned bamboo shoots
(Thailand, 2006)
Inadequate heat treatment 209 (0) I A [33,34]
Commercial pasteurised carrot juice
(Canada & USA, 2006)
Safety relied on refrigeration;
refrigeration inadequate
6 (1) I A [35,36]
Commercially produced sausages
(China, 2007)
Production unknown, no refrigeration 66 (0) I A [37]
Commercially canned chilli sauce
(USA, 2007)
Deficient canning process 8 (0) I A [38,39]
Home-packed, unprocessed black
olives? (Dutch tourists)
(Turkey, 2008)
Unknown 8 (0) I? B [40]
Commercial chicken enchiladas
(France, 2008)
Product pasteurised, probably stored at
room temperature for 2 weeks.
Reheated by microwaving
2 (0) I A [41]
Home-canned green beans/carrots
(USA, 2008)
Inadequate heat treatment 4 (0) I A [30]
Prepared vegetables
(Rwanda, 2009)
Poor preparation (?) 64 (2) I? B [30]
Commercial vacuum-packed, hot-
smoked whitefish
(France, 2009)
Temperature abuse (?) 3 (0) II E [42]
Commercial products, artichoke
preserve; cream of vegetable soup
(unlinked cases)
(Italy, 2010)
Products pasteurised. Refrigeration not
specified or only suggested. Long
shelf-life
2 (0) I? B [43]
Home-prepared ham (2 outbreaks)
(France, 2010)
Inadequate processing 10 (0) II B [44]
Commercial curry sauce in jar
(UK, 2011)
Controlling factor (pH), not as
specified
3 (0) I A [45]
Commercial olives stuffed with
almonds (from Italy)
(Finland, 2011)
Product pasteurised. No inhibitory
conditions reported
2 (1) I B [46]
(continued on next page)
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Table 2 (continued )
Outbreak Probable cause of outbreak Number of
cases (deaths)
C. botulinum
Group
Toxin type Reference
Commercial (artisan) ground green
olive paste
(France, 2011)
Inadequate heat treatment 9 (0) I A [47]
Commercially produced potato soup (2
unlinked cases)
(USA, 2011)
Not refrigerated 2 (0) I A [48]
Illicit prison alcohol “pruno”, made
with potatoes
(USA, 2011)
Mild heat treatment, maintenance at
ambient temperature
8 (0) I A [49]
Home-made olive and tuna pate (?)
(Spain, 2011)
Temperature abuse 2 (0) I A [50]
Illicit prison alcohol “pruno”, made
with potatoes (2 outbreaks)
(USA, 2012)
Mild heat treatment, maintenance at
ambient temperature
12 (0) I A [51]
Home-prepared ham
(France, 2012)
Inadequate processing 2 (0) II B [44]
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within the neurotoxin gene cluster may vary; some type A1
strains with an orf-X cluster possess an extra 0.6 kb between
the orf-X2 and orf-X3 genes, and the Ba4 strain, CDC 657,
shares the feature of an extra 1.2 kb between the orf-X1 and
botR (p21) genes with the type A3 strains [20]. More subtly,
the promoter region of the botR gene of type A5 strains lacks
a 76 nucleotide (nt) region which encompasses the sigma
factor binding sites thought to be required for autoregulation
of BotR [21,22].1.3. Foodborne botulismBotulism is a severe disease of humans and animals, with a
high fatality rate (ca. 5e10% of cases). Typical symptoms are
flaccid muscle paralysis; often initially blurred vision, fol-
lowed by an acute symmetrical descending bilateral paralysis,
and if not treated, ultimately paralysis of the respiratory or
cardiac muscles. If severe cases are not fatal, then full re-
covery may take months or even years. There are three major
types of botulism in humans; infant/intestinal (adult) botulism,
wound botulism and foodborne botulism. Infant/intestinal
(adult) botulism is an infection associated with cell multipli-
cation and neurotoxin formation in the gut, and wound botu-
lism is an infection associated with cell multiplication and
neurotoxin formation in a wound (often following drug abuse).
Foodborne botulism is an intoxication caused by consumption
of neurotoxin pre-formed in the food. The successful preven-
tion of foodborne botulism depends on (i) identifying appro-
priate control measures when new processing technologies are
introduced or modified, and (ii) ensuring that these effective
control measures are applied correctly. This requires the
control of two physiologically distinct bacteria (C. botulinum
Groups I and II, see Table 1). The commercial implications of
foodborne botulism can be very severe. For example, in New
Zealand in 2013, a milk product was recalled that was not
associated with any cases of botulism, but suspected of being
contaminated with C. botulinum (ultimately found to be free ofcontamination), and according to newspaper reports cost
hundreds of millions of dollars.
The failure to effectively apply the botulinum cook
(121 C/3 min) to canned or bottled foods has led to many
outbreaks of foodborne botulism associated with C. botulinum
Group I [23e51](Table 2). For example, a large outbreak in
Thailand in 2006 (209 cases) was associated with consumption
of inadequately home-canned bamboo shoots [33,34]. Inade-
quate thermal processing of cans of a commercial hot dog
chilli sauce in 2007 in USAwas associated with eight botulism
cases, and initially led to the recall of 39 million cans, then an
expanded recall of 111 million cans [39]. The canning facility
was eventually closed. Temperature abuse of foods intended to
be stored chilled has also been responsible for several severe
outbreaks of foodborne botulism, including those associated
with commercial chilled carrot juice and commercial chicken
enchiladas (Table 2). A number of recent outbreaks of food-
borne botulism in the USA have been associated with illicit
prison alcohol (”pruno”) (Table 2).
Strains of C. botulinum Group II forming type B neuro-
toxin are often associated with foodborne botulism and meat
products in Europe, and sometimes with fish products in
North America [52e57]. It is likely that the first strain of C.
botulinum isolated by van Ermengem in 1895, following an
outbreak of foodborne botulism in Belgium associated with
salted ham, was a strain of C. botulinum Group II type B [58].
Recent foodborne botulism outbreaks in Iceland (at least one
associated with blood sausages), UK (jar of home-preserved
pork from Poland), and France (home-prepared ham) were
also associated with C. botulinum Group II type B [44,57].
Botulism outbreaks involving C. botulinum Group II type E
have been most frequently associated with fish (e.g. vacuum,
smoked, salted, dried), and home-prepared foods in the north
of Canada and Alaska (e.g. fermented beaver tail and paw,
“muktuk”) (Table 2). For example, a botulism outbreak in
France in 2009 (3 cases) was associated with consumption of
commercial vacuum-packed hot-smoked whitefish in which
C. botulinum Group II type E had grown and formed
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Minimally heated, chilled foods are a current concern
[5,6,59,60].1.4. Whole genome sequencing and C. botulinumIn 2007, the first genome of a strain of C. botulinum was
published (Group I strain ATCC 3502) [61]. This article pro-
vided the first insights into the genome of a strain of C. bot-
ulinum, and heralded the start of a new era of C. botulinum
genomics. The sequence of a number of C. botulinum genomes
is now available in public databases. The cost of genome
sequencing has fallen by many orders of magnitude over
recent years, and a number of large genome sequencing pro-
jects are presently in progress. These will extend our under-
standing of the biology of the organisms that are C. botulinum.
Our present knowledge of the genomics of C. botulinum
Groups I and II is detailed below. The sequencing of botuli-
num neurotoxin genes and their associated clusters started
more than twenty years ago, but has been considerably
accelerated by advances in whole genome sequencing. This
resulted in an appreciation of the variability of botulinum
neurotoxin genes and their associated gene clusters. CurrentFig. 2. ACT comparisons of C. botulinum genomes. Red blocks indicate DNA hom
linear horizontal black bars, with the gene annotated as coming first after each ori
Group I genomes of strains forming neurotoxins types A, B and F. B: C. botulinum G
of the C. botulinum Group I strain ATCC 3502, the C. botulinum Group II strain E
the contigs available in GenBank for the unfinished genome of C. sporogenes ATCC
below the black bar representing the genome of ATCC 15579 are coloured a
ABKW02000002); light blue, contig 478 (ABKW02000003); green, contig 493 (A
indicate whether the contigs have been reverse/complemented in order to respect the
apart, also in order to match this genome. D: Genomes of the C. botulinum Groupunderstanding of neurotoxins formed by strains of C. botuli-
num Groups I and II is described in this review.
2. Genomics of C. botulinum Groups I and II2.1. Comparison of whole genome sequencesThe first genome to be published was that of C. botulinum
Group I strain ATCC 3502 [61]. The genome comprised a
chromosome (3.89 Mb) and a small plasmid (16.3 kb) that
encoded a bacteriocin. The genome had a low G þ C content
(28.2%). Other strains of C. botulinum Group I that have been
subsequently sequenced have been found to be highly similar.
The genomes of strains of C. botulinum Group II are of a
similar size, and have a marginally lower G þ C content
(27.5%) [62].
The genomes of strains of C. botulinum Group I that form
type A, B, or F (but not type H) neurotoxin are presently
available for analysis. Three commonly studied strains of C.
botulinum Group I are ATCC 3502 (type A1), Okra (type B1)
and Langeland (type F1). The genomes of these three repre-
sentative strains have been compared using the Artemis
Comparison Tool (ACT, [63]), a software programme freelyology (>90%) between paired genomes. Circular genomes are represented as
gin of replication positioned at the left hand end of each bar. A: C. botulinum
roup I genomes of strains forming neurotoxin subtypes A1 e A5. C: Genomes
klund 17B, and the non-neurotoxigenic C. sporogenes ATCC 15579. Note that
15579 have been manually edited to generate a ‘best fit’ genome. The arrows
ccording to contig number: red, contig 488 (GenBank accession number
BKW02000004); dark blue, contig 486 (ABKW02000001). The arrows also
genome of ATCC 3502, and that two contigs (478 and 488) have been broken
II strains Beluga, Alaska and Eklund 17B.
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Table 3
Location and accessory gene status of C. botulinum Group I neurotoxin gene clusters.
Neurotoxin
subtype
Representative
strain
Neurotoxin
cluster
Neurotoxin
cluster location
Neurotoxin cluster locus Accession number
A1 ATCC 3502 ha Chromosome oppA/brnQ AM412317
A1(B) NCTC 2916 orf-X, ha Chromosome arsC (oppA/brnQ) ABDO02000001-49
A2 Kyoto-F orf-X Chromosome arsC CP001581
A2b5 CDC 1436 Unknown Plasmid Unknown [70]
A2f4f5 Af84 orf-X Chromosome arsC, pulE, plasmid-borne site AOSX00000000.1
þPlasmid AOSX01000021.1
A3 Loch Maree orf-X Plasmid Plasmid-borne site CP000962
B5a4 CDC 657 ha, orf-X Plasmid Plasmid-borne site CP001081
A5(B0) H04402 065 ha Chromosome oppA/brnQ FR773526
B1 Okra ha Plasmid Plasmid-borne site CP000940
B1 CDC 1632 Unknown Chromosome Unknown [70]
B2 CDC 1828 Unknown Chromosome Unknown [70]
B2 ISS-333 Unknown Plasmid Unknown
B3 CDC 816 Unknown Chromosome Unknown [70]
A2b3 ISS-87 Unknown Plasmid Unknown
B5f2 Bf ha, orf-X Plasmid Plasmid-borne orf-X and
ha cluster sites
ABDP010000023,-18,-34,
69 (4 contigs)a
F1 Langeland orf-X Chromosome arsC CP000728
a Four contigs from the unassembled genome identified as showing regions of homology to other neurotoxin cluster-bearing plasmids were assembled manually
[69]. Ref. [70], a PFGE analysis, has been cited where more specific information is unavailable.
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Fig. 2A shows the results of this comparison, with ATCC 3502
in the centre, Okra at the top, and Langeland at the bottom.
The red blocks in the graphic which connect each genome
(represented as a black horizontal bar) depict regions of high
(>90%) homology. It is apparent that although forming sero-
logically distinct toxin types, these C. botulinum Group I ge-
nomes are closely related, displaying relatively minor
insertions/deletions of genetic information with respect to
each other.
Within each neurotoxin type, with the exception of G, a
number of subtypes have been identified. For example, the
genomes of strains forming five type A subtypes (termed A1,
A2, A3, A4, and A5) are presently available [12,64]. Fig. 2B is
an ACT comparison of the genomes of strains which each
form one of the subtypes A1-A5. As before, although clear
differences in DNA identity can be observed, these are
confined to relatively small regions, spanning up to 90 genes
(the largest white gap in the comparison between the A3 and
A4 strains in Fig. 2B). The level of sequence identity is very
similar to that seen in Fig. 2A, thus at this level of analysis,Fig. 3. Heatmaps and dendrograms generated by two colour microarray analysis
botulinum Group II (panel B). Microarray probes for the C. botulinum Group I analy
C. botulinum Group II analysis from the genome sequence of Eklund 17B [62]. Com
by mixing genomic DNA of strain ATCC 3502 with that of the test strain, each DN
microarray. Similarly, labelled DNA from strain Eklund 17B was used as the hybrid
yellow colour signals that the test strain genome shares >85% homology with a gen
present (with the caveat that due to the small size (60 nt) of each microarray probe,
background ‘noise’ which has to be normalised during data processing). The bot
represents the result of hybridising the reference strain DNA for each Group with its
of microarray probes which for technical reasons have failed to hybridise to their co
types formed, while the Group II clades (panel B) do respect neurotoxin types form
most closely related to Eklund 17B (hence the greater proportion of yellow bars istrain ATCC 3502 (type A1) does not appear to be more
closely related to the strains forming other type A neurotoxins
than to strains forming type B or F neurotoxins. Similar ob-
servations were also made using a DNA microarray based on
the genome of strain ATCC 3502, with the microarray analysis
also revealing more subtle differences (section 2.2). It is,
however, apparent that all of these strains of C. botulinum
Group I exhibit synteny.
Once we stray from the boundaries defined by membership
of C. botulinum Group I, DNA sequence homology rapidly
declines. Fig. 2C demonstrates this quite dramatically with a
comparison between the genomes of C. botulinum Group I
ATCC 3502, and C. botulinum Group II Eklund 17B. The ACT
comparison software struggles to find enough homology to
assign any red blocks at all. In contrast, although designated as
a different species by virtue of its failure to form botulinum
neurotoxin, C. sporogenes ATCC 15579 shares enough iden-
tity with ATCC 3502 to confuse a taxonomist who was un-
aware of its toxin status. The ACT analyses presented here
confirm the results of a previously described microarray study,
where an array based on the genome of ATCC 3502 wasof genomic DNA from strains of C. botulinum Group I (panel A) and of C.
sis were derived from the genome sequence of ATCC 3502 [61,65] and for the
petitive hybridisations for the C. botulinum Group I analyses were performed
A having been labelled with a different fluorescent dye, before adding to the
isation reference for the C. botulinum Group II experiments. In each heatmap, a
e probe on the microarray, generally implying that a very similar gene may be
false signals may be generated by small sequence differences, giving a level of
tom, horizontal lane of each heatmap is an internal control experiment, and
elf; any bars which lack a yellow colour in these two lanes indicate the position
gnate DNA sequence. The Group I clades (panel A) do not respect neurotoxin
ed; i.e. clade 3 ¼ type E, clade 2 ¼ type B or type F, clade 1 ¼ type B strains
n these heatmaps).
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meaningful family tree, but completely failed when used with
DNA from Eklund 17B [65].
At present, fewer complete genomes from C. botulinum
Group II are available for study. However, comparison of the
genomes reveals clear regions of high homology, but the gaps
in between the red blocks seem to be larger and more frequent
than for C. botulinum Group I (Fig. 2D). This suggests that C.
botulinum Group II is more diverse than C. botulinum Group I,
confirming earlier studies that used alternative approaches
[15]. In addition, the blue blocks, which represent DNA
sequence inversions with respect to the genome with which it
is compared, are also more obvious. Interestingly, the genome
of strain Alaska, which forms neurotoxin type E3, carries a
large region at its centre (in this linear depiction) which is
inverted with respect to the genome of Beluga (type E1) and of
Eklund 17B (type B4). The genome of Beluga was used twice
in this instance (top and bottom) to demonstrate that the
inversion is indeed in the Alaska genome, as Beluga aligns
quite well with Eklund 17B (Fig. 2D). The significance of this
apparent inversion in the Alaska genome is not known at
present.2.2. Comparison using DNA microarraysDNA microarrays provide an alternative to whole genome
sequencing for analysis of whole genomes; they are particu-
larly useful for comparison of many closely related genomes,
using a well-characterised, sequenced strain as a hybridisation
reference. Fig. 3 displays the main set of results from two
different studies, in which a DNA microarray was used to
compare sequences representing all predicted genes of the
sequenced C. botulinum Group I strain ATCC 3502 with the
unknown ones of several strains of the same Group (Fig. 3A),
and similarly all predicted genes of the Eklund 17B genome
were compared with unknown ones from other members of C.
botulinum Group II (Fig. 3B). Strains tested using the C.
botulinum Group I microarray included those forming type A,
A(B), B, Bf and F neurotoxins, plus several examples of the
closely related but non-toxigenic C. sporogenes. Strains tested
using the C. botulinum Group II microarray included those
forming type B, type E or type F neurotoxin [62,65].Table 4
Location and accessory gene status of C. botulinum Group II neurotoxin gene clu
Neurotoxin subtype Representative strain Neurotoxin cluster Neurot
B4 Eklund 17B ha Plasmi
E1 Beluga orf-X Chrom
E1 CB11/1-1 orf-X Plasmi
E3 Alaska E43 orf-X Chrom
E9 CDC 66177 orf-X Chrom
F6 IFR 06/001 orf-X Chrom
Strain Eklund 17B has been independently sequenced by two institutes; the two a
plasmid.
Note: no genome sequence data are available for subtypes E2, E6, E7 and E8. Subty
a The neurotoxin gene cluster-bearing plasmid of C. botulinum Group II type B
b Sequence of a 50 kb region of the chromosome containing the neurotoxin genWhen presented side-by-side for the first time, the simi-
larities and differences between C. botulinum Groups I and II,
as demonstrated by ACT analysis (Fig. 2), become readily
apparent. The greater quantity of yellow colour in the heatmap
for C. botulinum Group I than for C. botulinum Group II
further confirms that the genetic variation between members of
C. botulinum Group I is much less than that apparent for
members of C. botulinum Group II (Fig. 3). Furthermore, the
coloured lines at the left of each dendrogram in Fig. 3 indicate
the type of neurotoxin formed by the tested strain. In the case
of C. botulinum Group I, although some groupings are clearly
noticeable, the clustering of strains according to the majority
of the genetic information contained on the chromosome (i.e.
clades on the right hand side of Fig. 3A) does not always align
according to the type of neurotoxin formed (Fig. 3A). Inter-
estingly, strains of C. sporogenes fitted well with the C. bot-
ulinum Group I strains [65]. That said, a recent genetic and
functional study of spore germination receptors showed there
to be significant physiological differences between C. spor-
ogenes and C. botulinum [66]. The position with C. botulinum
Group II is, however, very different (Fig. 3B). C. botulinum
Group II can be relatively easily organised into only three
clades, mostly true to their neurotoxin type, suggesting that
horizontal transfer of neurotoxin gene clusters occurs less
frequently in C. botulinum Group II than in C. botulinum
Group I. This is particularly striking for strains which form
type E neurotoxin, which group together in a clade that is
obviously genetically well-separated from those that form type
B or type F neurotoxin. This genetic homogeneity may be due
to a better defence strategy against invading foreign DNA, less
overall recombinogenicity of DNA, or may simply reflect the
geographical isolation of clades within C. botulinum Group II.
Comparison of the large, seemingly unbroken blocks of
synteny shared by the B and E serotypes that are displayed in
the ACT figures, and the number of blocks coloured blue in
the Group II microarray heatmap hints at an inconsistency
between these analyses (Figs. 2 and 3). The reason for this
apparent discrepancy is that very small sequence differences
(often of only one or two nucleotides) were found to affect
hybridisation of test DNA to the microarray 60-mer gene
probes, generating false negatives; whereas the ACT analysis,
based on an average sequence identity over a much greatersters.
oxin cluster location Neurotoxin cluster locus Accession number
d Plasmid-borne sitea FR745876, CP001057
osome rarA ACSC000000001-16
d Plasmid-borne site AORM01000001-171
osome rarA CP001078
osome rarA ALYJ01000001-119
osome topB KC516868b
ccession numbers are for both versions of the neurotoxin gene cluster-bearing
pes E4 and E5 are found exclusively in strains of neurotoxigenic C. butyricum.
4 does not display synteny with those of C. botulinum. Group I
e cluster.
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homology match at approximately 90% or greater. That said,
the higher degree of false negative results from the microarray
analysis did not seem to greatly influence the placement of
each strain within its appropriate clade.
The apparent insertion of a cluster of C. botulinum Group
II type F strains into the C. botulinum Group II type B clade
(Fig. 3B, group of green-coloured tree branches surrounded
by red-coloured ones) led to a more detailed investigation,
using high density genome sequencing. This revealed evi-
dence for an insertion of 34 kb of foreign DNA, containing
the type F6 neurotoxin gene cluster, into a chromosome that
is otherwise very closely related to that of a C. botulinumFig. 4. Dendrogram generated by pairwise comparison of the coding region of C. bo
GenBank that are identical to subtypes A1 and A2 depicted in this dendrogram ha
used to generate the tree branch points are positioned above the major branches.Group II type B4 [9]. Since all C. botulinum Group II type B4
strains so far examined carry their neurotoxin gene cluster on
a plasmid, it is possible that loss or integration of parts of this
plasmid may have represented one of the several evolutionary
steps that would be required to produce the current type F6
genome [9].
Furthermore, the apparent lack of horizontal transfer of
neurotoxin gene clusters in C. botulinum Group II, compared
to that observed for C. botulinum Group I, contrasts with the
frequency of occurrence of similar neurotoxin gene clusters in
either a chromosomal or plasmid location in the latter (Tables
3 and 4). The fact that in all C. botulinum Group II type E and
F strains, the neurotoxin gene cluster is inserted into a genetulinum Group I neurotoxin gene subtypes A1-A5. Many examples available in
ve been omitted for clarity. Approximate values for the nucleotide differences
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represents an extra level of ‘genetic effort’ required to
circumvent a normally very robust system to prevent inte-
gration of foreign DNA into the chromosome of C. botulinum
Group II.
3. Neurotoxin gene clusters of C. botulinum Groups I and
II3.1. Location and mobility of neurotoxin gene clustersThe results from microarray analyses suggested that in C.
botulinum Group I, neurotoxin gene clusters did not respect
conventional vertical routes of heredity, but rather demon-
strated an apparent ability to be acquired by horizontal
transmission [65]. These observations added strength to the
findings from early DNA sequencing experiments, which had
revealed the presence of bacterial insertion sequence (IS) el-
ements flanking the 5’- and 3’- boundaries of many neurotoxin
gene clusters [61,67]. Insertion sequence elements (IS ele-
ments) are short sequences of DNA that encode transposase
enzymes that promote their translocation and contribute to
genetic recombination between bacteria; those found flanking
C. botulinum neurotoxin gene clusters are usually non-Fig. 5. Dendrogram generated by comparison of neurotoxin genes of C. botulinum G
branch points are positioned above the major branches.functional and incomplete [68], but their presence suggested
the possibility that they had been involved in horizontal
acquisition of the neurotoxin gene cluster. The availability of
genome sequences has made it possible, for the first time, to
test this hypothesis by searching for signs of insertion of
neurotoxin gene clusters into a previously undisturbed region
of a bacterial chromosome. At present, three sites of chro-
mosomal insertion, oppA/brnQ, arsC and pulE have been
identified for C. botulinum Group I; and two, rarA and topB
have been identified for C. botulinum Group II [7,9,69]. Table
3 summarises the present state of knowledge regarding the
neurotoxin gene clusters of C. botulinum Group I, with respect
to accessory gene status (i.e. ha or orf-X ), whether the
neurotoxin gene clusters occur singly or multiply within a
genome, and if known, the chromosomal locus for each
cluster. There are several examples where the neurotoxin gene
cluster of a specific neurotoxin subtype can be found on a
plasmid or on the chromosome [69,70](Table 3). ACT com-
parisons have demonstrated large regions of synteny between
neurotoxin gene cluster-bearing plasmids of C. botulinum
Group I, to the extent that it can be postulated that these too
share preferred sites of insertion for the neurotoxin gene
cluster [7,69]; however these have not yet been formalised by
identification of flanking genes of known function. For C.roup I type A1. Values for the nucleotide differences used to generate the tree
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accessory gene status (i.e. ha or orf-X ), and neurotoxin gene
cluster location (plasmid or chromosomal locus) for each
cluster is summarised (Table 4). Less is known about the
neurotoxin gene clusters of C. botulinum Group II, as indi-
cated by the relative sizes of Tables 3 and 4. At the time of
writing, large-scale genome sequencing programmes are un-
derway, including those for C. botulinum Group II, so this
disparity may soon be addressed. Interestingly, horizontal
transmission of neurotoxin gene clusters is less evident
amongst members of C. botulinum Group II [9,62]. Until
recently the only sequenced genome was that of strain Eklund
17B, which carries the type B4 neurotoxin gene cluster on a
plasmid [62]. More recently, the sequences of ten more
neurotoxin gene cluster-bearing plasmids of C. botulinum
Group II type B4 have been published [57]. As with the
plasmid of Eklund 17B [68], there is very little homology of
these with any known plasmid from C. botulinum Group I;
although these 11 type B4 plasmids share large regions of
synteny amongst themselves and they represent a closely
related cluster within C. botulinum Group II. The neurotoxin
gene cluster of strains of C. botulinum Group II type E appears
to be most frequently located on the chromosome, although
PFGE analysis has recently revealed the presence of three
strains of C. botulinum Group II type E1 that possess aFig. 6. Dendrogram generated by pairwise comparison of the coding region of C. b
differences used to generate the tree branch points are positioned above the majorneurotoxin gene cluster-bearing plasmid of about 146 kb [71].
The neurotoxin gene cluster of strains of C. botulinum Group
II type F is chromosomally-located [9]. Further information on
the type E1 plasmids and any others from C. botulinum Group
II is needed before any meaningful analysis of preferred
insertion site of the neurotoxin gene cluster within plasmids
can be carried out.3.2. Neurotoxin serotypes and neurotoxin gene subtypesSerological methods were first used to distinguish botuli-
num neurotoxins more than a century ago. Initial work by
Leuchs demonstrated that botulinum neurotoxins formed by
two European strains of C. botulinum were antigenically
distinct, with antitoxin raised against one neurotoxin not cross-
neutralising neurotoxin formed by the other strain [72]. Later,
Burke recognised two antigenically distinct botulinum neu-
rotoxins, and designated these as types A and B [73]. This
work established the use of serological methods based on type-
specific antitoxin to distinguish botulinum neurotoxin sero-
types, and has now led to the recognition of seven confirmed
botulinum neurotoxin serotypes, types AeG, with a recently
identified type H that remains to be verified [11,17]. However,
it soon became obvious that there was also some variation
within a single botulinum neurotoxin type.otulinum Group I and II type B genes. Approximate values for the nucleotide
branches.
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vation of their amino acid sequence has rapidly advanced our
understanding of the neurotoxins. It has been found that the
amino acid differences between the seven neurotoxin sero-
types (A to G) range from 37.2% to 69.6% [12]. Importantly,
the classification of neurotoxin types based on the use of
serological methods has been supported. Additionally, novel
findings have been made on the variation within a single
neurotoxin type with more than thirty neurotoxin subtypes
described in the literature [12]. However, this has led to a
debate on what might constitute a botulinum neurotoxin type
or subtype. For example, should neurotoxin types continue to
be defined on the basis of traditional serological methods or
instead should they be based on the derived protein sequence?
In a similar manner, how should a neurotoxin subtype be
defined? We are probably moving towards the classification of
botulinum neurotoxin types based on the derived protein
sequence. The definition finally adopted needs to be an oper-
ational definition that is entirely consistent with the traditional
serological approach. An advantage of a sequencing-based
approach is that it is possible to compare neurotoxins
formed by strains present in different laboratories; the transfer
of strains between laboratories being heavily restricted by
bioterrorism concerns.
In 2005, it was proposed that a C. botulinum neurotoxin
gene might be defined as a subtype if it encoded a protein
sequence that differed from the standard neurotoxin type by at
least 2.6% [74]. Since then, many neurotoxin gene sequences
have been determined, and some commonly accepted sub-
types, for example type B3, differ from their closest relatives
by less than 2.6% at the amino acid level [75]. Moreover, not
all amino acid substitutions would have the same impact on
the biological function of the neurotoxin, including its ability
to be neutralised using the traditional antibody-based ap-
proaches. To this end, it has been proposed that newly
discovered neurotoxin gene variants be named as such, until it
has been established that they display different neurotoxin
biology such as toxicity, antigenicity or substrate cleavage site
[76]. The importance of the genetic background in which theFig. 7. Dendrogram generated by comparison of neurotoxin genes of C. botulinum
number X71343 was published as being that of Eklund 17B [77]; however it d
Approximate values for the nucleotide differences used to generate the tree branchneurotoxin gene is found has also been emphasised [20].
Certainly, the current position is ill-defined and inconsistent,
and a rational approach is required within the botulinum
community. As more and more neurotoxin gene sequences
appear, boundaries have become blurred, and to highlight this
we have reviewed the position with regard to C. botulinum
Group I type A and its subtypes, and C. botulinum Groups I
and II type B and its subtypes, as examples.
The neurotoxin gene sequence of five type A subtypes (A1
to A5) are available from GenBank. A dendrogram has been
generated by pairwise comparison of these sequences (Fig. 4).
Many more sequences are deposited, but are identical to those
included here. As an indicator of scale, the main group of type
A2 genes are within 2 nt of identity to each other; Mascarpone
and CDC 2171 differ by 9 and 37 nt, respectively, to Kyoto-F.
In the A3 group Loch Maree differs by 8 nt to the three CDC
540XX examples, which are identical to each other; Loch
Maree differs by 143 nt to Kyoto-F and by 333 nt to the CDC
657 A4 gene. This gene in turn differs by 250 nt to the A5
genes, which differ by 53 nt to the A1 gene of ATCC 3502.
Interestingly, the type A genes of CDC 41370, CDC 41376,
217-12, 2008-148 and CDC 54068 are placed separately, be-
tween the A1 and A4 branches, which indicates that some or
all of them may represent a new subtype [67]; as an example,
CDC 41376 differs by 249 nt to the A4 gene, and by 87 nt to
the A1 gene of ATCC 3502. The A2 neurotoxin gene of CDC
2171 also displays sufficient diversity from the main body of
type A2 genes to have been noted as another possible candi-
date for a new subtype [76]. Indeed a recent review has
identified ten type A subtypes [17]. In summary, considering
the genes encoding botulinum neurotoxin serotype A only, the
DNA sequence identity of the different subtypes can vary from
2 nt to 333 nt.
Close examination of Fig. 4 hints at the presence of
distinct sub-groups within the branch containing the type A1
genes. A similar pairwise alignment was performed using
only type A1 gene sequences, generating a dendrogram
(Fig. 5). Information for strains 73A, BS-A, Cam2A, CDC
42961 and CDC 59755 was derived from microarray dataGroup II subtype B4 (modified from Ref. [57]). The sequence with accession
iffers from the two other published versions (which are identical) by 21 nt.
points are positioned above the major branches.
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GSM402932, GSM402918 and GSM402936, respectively).
Information for CDC 54068 is limited to sequence of the
neurotoxin gene only (GenBank JX127207). It can be seen
that all type A1 genes are very closely related; using ATCC
3502 as an arbitrary standard, the A1 gene of Allergan-Hall A
differs by only 1 nt; those of the NCTC 2916 cluster by 2 nt,
those of the CDC 297 cluster by 5 nt and CDC 54068, which
featured as an outlier in Fig. 5, by 12 nt. The three main
groups are labelled according to the status of their ha or orf-X
neurotoxin gene cluster, also whether the A1 gene is in a
genetic background which includes a B gene (expressed or
silent). Even though the number of single nucleotide poly-
morphisms (SNPs) separating the groups in this dendrogram
is small, nevertheless there is a correlation between genetic
background and type A1 cluster.
Type B neurotoxin is formed by strains of C. botulinum
Groups I and II, and the type B neurotoxin gene sequences are
compared (Fig. 6). Considering the large genetic and physio-
logical gap which separates C. botulinum Groups I and II, it is
perhaps not surprising that each type B subtype appears to be
exclusive to C. botulinum Group I or Group II. Subtype B4
appears to be only found in C. botulinum Group II, while all
the other subtypes are solely located in C. botulinum Group I.
This may indicate that a window of opportunity for horizontal
gene transfer of type B toxin genes between the two C. bot-
ulinum Groups in the distant evolutionary past has now closed.
(It is noted, however, that while the C. botulinum Group II
strain Prevot 59 in our laboratory possessed the type B4
neurotoxin gene, the version of this strain examined by Hill
possessed the type B2 neurotoxin gene [75]). The cluster at top
left of Fig. 6, which is designated ‘B?’ contains type B genes
that are described as type B1 (M-18/3) and type B2 (Osaka06,
CDC 6291, 115B), but in this analysis seem to form a separate
group (subtype information for strain 115B was derived from
microarray data, GEO accession number GSM402938). This
appears to be yet another example of C. botulinum neurotoxin
genes which fail to fit into a nicely defined subtype box.
Analysis of the gene sequence of the neurotoxin subtype B4
reveals further subdivisions (Fig. 7). All of the type B4 genes
examined so far are located on an extra-chromosomal element.
Recently the sequence of eleven of these, all carried by a
plasmid, has been published [57]. Based on this recent work
and previous studies, three main sub groups within the type B4
subtype have been identified [57,75,77,78] (Fig. 7). It seems
that small genetic differences between the neurotoxin genes, at
the SNP level, are not random but become fixed and are
associated with a particular subdivision. For strains that
formed type A1 neurotoxin, the subdivisions were associated
with a specific genetic background (Fig. 5), but this does not
seem to be the case for strains that form type B4 neurotoxin
[57]. However the three different types of plasmid identified
which carry the type B4 neurotoxin gene cluster, do show a
link with geographic location [57].
As both the cost and difficulty of bacterial genome
sequencing continues to lessen, and the computing power
needed to perform analysis of the data subsequently producedbecomes more readily available, it can be expected that new C.
botulinum neurotoxin serotypes and their subtypes will be
identified, and that unexpected genome organisations will be
uncovered. A perfect example of this was described recently
by Raphael and colleagues, who identified the C. botulinum
Group II type E strain CDC 66177, previously isolated in
Argentina in 1995, as not only forming a new neurotoxin
subtype (E9), but also enjoying a chromosomal organisation
that appears to respect that of the C. botulinum Group II type
B forming strain, Eklund 17B more than that of published
examples of type E strains such as Alaska or Beluga [79].
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